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AbstrACt
Introduction Lung cancer is the most common cause 
of cancer mortality in the UK, and non-small-cell lung 
cancer (NSCLC) accounts for approximately 85% of all 
lung cancers. Most patients present with inoperable 
disease; therefore, radiotherapy plays a major role in 
treatment. However, the majority of patients are not 
suitable for the gold standard treatment (concurrent 
chemoradiotherapy) due to performance status 
and comorbidities. Novel strategies integrating 
radiotherapy advances and radiobiological knowledge 
need to be evaluated in patients treated with 
sequential chemoradiotherapy. Four separate dose 
escalation accelerated radiotherapy schedules 
have been completed in UK (CHART-ED, IDEAL-CRT, 
I-START and Isotoxic IMRT). This study will compare 
these schedules with a UK standard sequential 
chemoradiotherapy schedule of 55 Gy in 20 fractions 
over 4 weeks. As it would be impossible to test all 
schedules in a phase III study, the aim is to use 
a combined randomised phase II screening/‘pick 
the winner’ approach to identify the best schedule 
to take into a randomised phase III study against 
conventionally fractionated radiotherapy.
Methods and analysis Suitable patients will have 
histologically/cytologically confirmed, stage III 
NSCLC and are able to undergo chemoradiotherapy 
treatment. The study will recruit 360 patients; 120 on 
the standard arm and 60 on each experimental arm. 
Patients will complete 2–4 cycles of platinum-based 
chemotherapy before being randomised to one of 
the radiotherapy schedules. The primary endpoint is 
progression-free survival, with overall survival, time to 
local–regional failure, toxicity and cost-effectiveness 
as secondary objectives.
Ethics and dissemination The study has received 
ethical approval (research ethics committee (REC) 
reference: 16/WS/0165) from the West of Scotland 
REC 1. The trial is conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice. Trial 
results will be published in a peer-reviewed journal 
and presented internationally.
trial registration number ISRCTN47674500.
IntroduCtIon
background
Lung cancer is the most common cause of 
cancer mortality in the UK. In 2014, there 
were 46 400 new cases and 35 900 deaths and 
non-small-cell lung cancer (NSCLC) accounts 
for approximately 85% of these. Most cases 
are inoperable at presentation; however, many 
patients with stage I–III disease can be treated 
radically using radiotherapy (RT), although 
survival rates are disappointing. Successful 
local control has been found to correlate 
with improved survival.1 Strategies to achieve 
improved local control rely on intensification 
of local antitumour effect through radiation 
sensitisation, acceleration of RT schedule 
or dose escalation. As most patients are 
not suitable for gold standard treatment of 
concurrent chemoradiotherapy, novel strat-
egies integrating RT technological advances 
and radiobiological knowledge need evalu-
ating in patients treated with the alternative 
option of sequential chemoradiotherapy. 
The UK strategy has been to develop separate 
escalation protocols for hyperfractionated 
strengths and limitations of this study
 ► Radiotherapy delivered using advanced techniques, 
including four-dimensional  CT and image-guid-
ed radiotherapy. Intensity-modulated radiotherapy 
is mandated in one arm and recommended in all 
others.
 ► Robust quality assurance programme.
 ► Innovative multiarm ‘pick the winner’ design.
 ► Not all experimental arms are available at all sites, 
so although arms are randomised against control, 
they are not randomised against each other.
 ► Final analysis relies on adjusting for between-centre 
differences in key patient characteristics in order to 
‘pool’ the control arm and achieve the target power.
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and once-daily schedules (CHART-ED,2 IDEAL-CRT,3 
I-START4 and Isotoxic IMRT5). These studies have 
completed recruitment and the results of two have been 
published.1 2 
dose acceleration/intensification
In the UK, Continuous Hyper-fractionated Accelerated 
Radiation Therapy (CHART) trial6 intensified local treat-
ment by accelerating the RT course. When compared 
with conventional fractionation, there was a 9% absolute 
improvement in 2-year survival (29% vs 20%; p=0.004) 
which provides evidence that intensification of local treat-
ment only results in increased overall survival (OS). This 
result is supported by meta-analysis7 reporting an abso-
lute benefit for hyperfractionated or accelerated RT over 
conventional fractionations of around 3% at 5 years.
Further evidence supporting intensification of local 
treatment comes from trials showing a survival benefit 
of concurrent chemoradiotherapy over sequential.5 This 
was achieved by chemotherapy increasing local tumour 
cell kill and improving local control while maintaining 
the systemic effect of chemotherapy.
rt dose escalation
Increasing the RT dose has been associated with seem-
ingly improved local control and OS in early-phase 
studies. However, Radiation Therapy Oncology Group 
06178 comparing 60 Gy in 30 fractions of radiotherapy to 
74 Gy in 37 fractions of radiotherapy once-daily showed 
that local control and OS were poorer on the higher 
dose. Reasons for this are being debated, but it is clear 
that increasing RT by 2 Gy per fraction per day with 
an increase in overall treatment time will not improve 
outcomes.
Isotoxic rt
The MAASTRO group pioneered the concept of ‘isotoxic 
RT’ allowing for individualised dose escalation using 
hyperfractionated accelerated RT based on predefined 
and mean lung dose in stage I–III patients. This showed 
with three-dimensional conformal RT delivered two times 
a day over 4 weeks that increasing the radiation dose to 
prespecified normal tissue dose constraints could lead 
to increased tumour control probability (TCP) with the 
same normal tissue complication probability.9 Survival of 
these stage III patients, all of whom were treated sequen-
tially, was comparable to results expected from concur-
rent chemoradiotherapy with acceptable acute and late 
toxicity. Since this study reported, intensity-modulated 
radiotherapy (IMRT) techniques have become routine 
practice improving targeting of radiation doses while 
decreasing doses to lungs and other normal tissue. This 
gives the potential to use the isotoxic approach to escalate 
the dose delivered to the target increasing TCP with the 
same normal tissue complication probability.10
dose acceleration and escalation
Techniques that avoid prolongation of overall treat-
ment time are attractive as they reduce the impact of 
accelerated tumour clonogen proliferation, which 
becomes clinically relevant for NSCLC approximately 3–4 
weeks after RT initiation. A meta-analysis7 of altered frac-
tionations (10 trials, 2000 patients with NSCLC) showed 
modified fractionation that improved OS as compared 
with conventional schedules (HR=0.88, 95% CI 0.80 to 
0.97; p=0.009), resulting in an absolute benefit of 2.5% 
at 5 years. CHART (54 Gy in 36 fractions of radiotherapy 
over 12 days) remains one of the more commonly used 
schedules for radical treatment of NSCLC in the UK 
along with daily fractionated schedules delivering 55 Gy 
in 20 fractions of radiotherapy over 4 weeks or 60–66 Gy 
in 30–33 fractions of radiotherapy over 6–6½ weeks.11 
In current UK practice, both CHART and the 4-week 
schedule are deliverable, with 99% of patients completing 
treatment, with survival outcome matching that seen in 
the original CHART study and very low levels of grade III/
IV toxicity.12 However, survival rates for all three regimens 
are low and could be improved by dose intensification.
Radiobiological modelling suggests that dose esca-
lation to improve the TCP is likely to be more effective 
if the overall treatment time is fixed rather than fixing 
the dose per fraction, and dose escalation typically adds 
1%–2% local control for each 1% increase in dose.13 
Therefore, Cancer Research UK (CRUK) funded four 
parallel dose-escalation studies to intensify accelerated 
schedules used in the UK. The first, CHART-ED (ISRCTN 
45918260)1 reported no dose-limiting toxicities with dose 
escalation (using additional twice-daily fractions of 1.8 Gy 
to 64.8 Gy in 17 days). This dose increase has the potential 
to increase local tumour control by 30%. The IDEAL-CRT 
trial (ISRCTN 12155469) evaluated dose escalation up 
to 73 Gy in 30 fractions of radiotherapy over 6-week 
schedule with dose escalation calculated on an individual 
patient basis according to either lung or oesophageal 
radiation dose. The study has established 68 Gy to 1 cc 
oesophagus as the maximum tolerated dose (MTD) to 
be taken forward into future trials.2 Both CHART-ED and 
IDEAL-CRT report encouraging 2-year survival figures: 
52% and 65%, respectively.
Following the confirmation of low toxicity with the 
original IDEAL-CRT trial, a further accelerated schedule 
was investigated where overall treatment time was short-
ened from 6 to 5 weeks by treating with RT twice a day 
on 1 day/week (not on chemotherapy day). The MTD to 
1 cc oesophagus was reduced to 65 Gy and the maximum 
prescription dose allowed was reduced to 71 Gy in 30 frac-
tions of radiotherapy (over 5 weeks). This portion of the 
study recruited 36 patients with a minimum 6-month 
follow-up and no excess toxicity. This schedule will be 
taken forward and given sequentially in ADSCaN (Accel-
erated, Dose escalated, Sequential Chemoradiotherapy in 
Non-small-cell lung cancer).
The two remaining studies, I-START (ISRCTN 
74841904),3 which individualised the RT dose simi-
larly to IDEAL-CRT using a schedule following sequen-
tial chemotherapy in 20 fractions of radiotherapy, and 
Isotoxic IMRT (NCT01836692),4 where patients were 
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treated twice daily over 4 weeks to a maximum of 79.2 Gy 
using prespecified normal tissue doses have completed 
recruitment and neither report excess toxicity (personal 
communication).
The gold standard treatment for stage III NSCLC 
is concurrent chemoradiotherapy.4 However, in prac-
tice guidelines can only loosely define eligibility for 
the concurrent approach14 and for many patients the 
concerns around fitness and the toxicity of this approach 
lead to chemoradiotherapy being given sequentially.15 
A recent analysis of the National Cancer Database16 
suggests there is a basis for these concerns and that there 
are categories of patients for whom the higher toxicity 
levels associated with the concurrent approach could 
prove detrimental. At this point of time, those categories 
are ill defined and novel strategies that integrate RT tech-
nological advances and radiobiological knowledge need 
evaluating in patients treated with sequential chemora-
diotherapy. This study aims to provide a framework for 
further development by identifying which is the best 
accelerated schedule to take forward into a randomised 
phase III study against conventionally fractionated RT.
MEthods And AnAlysIs
ADSCaN is a non-blinded multicentre phase II study spon-
sored by NHS Greater Glasgow and Clyde Health Board 
and coordinated by the CRUK Clinical Trials Unit (CRUK 
CTU) based at the University of Glasgow. It is registered on 
the ISRCTN clinical trials database (ISRCTN47674500) 
and funded by CRUK’s Clinical Trials Awards and Advi-
sory Committee (Funder Reference: C9759/A16604). 
RT quality assurance (QA) is supported by the National 
Radiotherapy Trial Quality Assurance (RTTQA) group. 
The study is included in the National Institute for Health 
Research (NIHR) Clinical Research Network port-
folio (ID 35624) and is being conducted in accordance 
with the Declaration of Helsinki and Good Clinical 
Practice.
We hypothesise that sequential chemoradiotherapy 
using accelerated, dose-escalated RT will improve 
progression-free survival (PFS), OS, time to local–
regional failure, toxicity and cost-effectiveness compared 
with conventionally fractionated sequential chemoradio-
therapy treatment. ADSCaN will take four dose-escalated 
accelerated sequential chemoradiotherapy schedules into 
a randomised phase II comparison with a UK standard 
sequential chemoradiotherapy using state-of-the art RT.
Patient and public involvement
Patient and carer representatives have been involved 
from the early stages of development of the ADSCaN 
study. These representatives had personal experience of 
sequential chemoradiotherapy treatment and ensured 
the study reflected their priorities in developing the 
most appropriate chemoradiotherapy regimens for this 
cohort of patients. Their engagement has been main-
tained through the National Cancer Research Institute 
Lung Clinical Studies Group and the West of Scotland 
Cancer Research Network Consumer Research Panel. 
In particular, we thank Tom Haswell who has become 
our consumer representative on the Trial Management 
Group (TMG) to help oversee recruitment and conduct 
of the study.
Detailed results of the study will be given the study 
participants/their relatives on request and disseminated 
on the publically accessible websites of our funders, 
CRUK, and other supportive charities (eg, Roy Castle 
Lung Cancer Foundation).
setting
ADSCaN opened on 22 August 2017 and will recruit 360 
patients with a histological/cytological proven NSCLC 
across 40 UK RT centres, a list of which can be found on 
the NIHR Clinical Research Network Portfolio. Patients 
will be stage III, performance status (PS) 0–1 and unsuit-
able for concurrent chemoradiotherapy. Individual 
centres will randomise patients between standard RT 
(55 Gy in 20 fractions of radiotherapy) and one or more 
experimental arms. All sites will offer the standard arm, 
but may choose which experimental arms they wish to use 
(figure 1: flow diagram).
Participant screening and selection
Patients deemed inoperable by the lung MDT and suit-
able for sequential chemoradiotherapy are invited to 
participate and provided with a patient information 
sheet (PIS, online supplementary appendix 1). Manda-
tory prerandomisation investigations include: lung func-
tion tests, contrast CT scan of thorax/upper abdomen 
within 4 weeks prior to randomisation and fluorodeox-
yglucose  PET with CT (or MRI) brain scan if patients 
have not these investigations prior to starting induction 
chemotherapy.
Inclusion criteria
 ► Histologically/cytologically confirmed stage III 
NSCLC.
 ► ECOG PS 0–2 (PS 2 only included if the local investi-
gator deems general condition is explained by disease 
or the primary chemotherapy treatment).
 ► Inoperable disease.
 ► Inoperable disease, unsuitable for concurrent chemo-
radiation, in the opinion of the treating oncologist.
 ► Patients with complete response, partial response or 
stable disease on CT assessment after 2 cycles of plati-
num-based chemotherapy.
 ► Aged ≥16 years.
 ► Adequate pulmonary function test results: forced 
expiratory volume in 1 s and/or diffusing capacity of 
lung for carbon monoxide transfer coefficient ≥40% 
of predicted.
Exclusion criteria
 ► Previous/current malignant disease likely to interfere 
with the protocol treatment or comparisons.
 ► Clinically significant interstitial lung disease.
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Informed consent
Eligibility is confirmed by a clinician and patients are 
given ≥24 hours to consider the PIS and ask questions 
prior to written informed consent being taken.
randomisation
Randomisation occurs after completion of chemotherapy. 
Once a patient is deemed eligible for the study and has 
consented to participate, the CRUK CTU, Glasgow, is 
contacted to confirm eligibility, and subsequently the 
patient is randomised to one of the available ADSCaN 
arms offered on-site and issued with a participant identi-
fication number. Patient enrolment details are confirmed 
by email.
Minimisation incorporating a random factor is used 
to allocate patients between treatment arms A:B:C:D:E 
so that an overall study ratio of 2:1:1:1:1 is achieved. The 
following stratification factors are used:
 ► Hospital.
 ► PS.
 ► Intention to use IMRT.
 ► Histological type.
 ► Stage.
 ► Epidermal growth factor receptor mutation status.
 ► Gross tumour volume (GTV).
 ► Haemoglobin.
 ► Serum albumin.
 ► Sex.
 ► Weight loss since diagnosis.
While on study, participants will not co-enrol in other 
clinical trials offering therapeutic intervention.
standard care
In patients with inoperable stage III NSCLC who are 
unsuitable for concurrent chemoradiotherapy, sequential 
chemoradiotherapy is the standard of care.
Patients who are eligible for this trial will receive 2–4 
cycles of platinum doublet neoadjuvant chemotherapy. 
The recommended non-platinum agents are peme-
trexed or vinorelbine for non-squamous carcinoma 
and gemcitabine or vinorelbine for squamous carci-
noma. TMG/DMC (Data Monitoring Committee) are 
aware that the standard of care for the systemic treat-
ment of stage III NSCLC may evolve over the course of 
this study and will consider the evolving evidence on 
newer approaches such as immunotherapy.
rt intervention and planning
Four-dimensional CT with intravenous contrast should 
be used for all ADSCaN patients to account for tumour 
motion during breathing. The whole thorax (cricoid to 
L2) should be covered to allow dose volume histograms 
to be calculated for the lung, heart, spinal cord, brachial 
plexus, great vessels, proximal bronchial tree and the 
oesophagus.
Figure 1 ADSCaN trial schema. ADSCaN, Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell 
lung cancer; EQD2, equivalent dose for 2 Gray fractions; IMRT, intensity-modulated radiotherapy; NSCLC, non-small-cell lung 
cancer.
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The input of a thoracic radiologist is recommended 
when defining the identifiable tumour and involved 
lymph nodes to give the GTV. The thoracic radiologist 
should work with a qualified radiation oncologist special-
ised in thoracic malignancies to produce a motion-
adapted GTV.
The 4D-GTV is expanded by 5 mm to create the clin-
ical target volume (CTV). The CTV will be expanded to 
include microscopic spread and may be edited to account 
for anatomical barriers but only if it is not thought to 
invade the structure.
CTV to planning target volume (PTV) expansion takes 
into account patient set-up uncertainties:
 ► If a centre is using per-fraction cone beam CT (CBCT) 
imaging and online correction for treatment verifica-
tion, the CTV should be expanded by 5 mm isotropi-
cally to create the PTV.
 ► If a centre is not CBCT imaging per fraction, the 
CTV should be expanded by 7 mm axially and 9 mm 
cranio/caudally to create the PTV.
Prescribed dose and fractionation
RT schedules should begin on a Monday where possible to 
reduce overall treatment time. Schedules are summarised 
in table 1, and dose constraints for organs at risk (OAR) 
are given in table 2.
All patients recruited at a centre must be treated with 
the same planning technique irrespective of randomisa-
tion arm. The use of IMRT is strongly recommended (and 
mandated for arm E) using five or more fields in an IMRT 
plan or an arc technique may be used.
Follow-up
Patients are followed up monthly for 3 months, then 
3-monthly to 2 years, 6-monthly to 3 years and then annually. 
A late toxicity assessment will be performed at each visit.
Withdrawal
Patients can withdraw from the trial at any time without 
any effect on clinical care.
Table 1 Summary of trial arms
Trial arm Total dose (Gy) Total fractions Fractions per day Total number of days
Arm A: Standard 55.0 20 1 26–28
Arm B: CHART-ED 54.0 36 3 Days 1–12
10.8 6 2 Days 15–17
Arm C: IDEAL-CRT 63–71 30 1 with 1 twice daily treatment per 
week
33–35
Arm D: I-START 55–65 20 1 26–28
Arm E: Isotoxic IMRT 61.2–79.2 34–44 2 23–30 depending on dose escalation
Table 2 Dose constraints for all trial arms
Volume Arm A: Standard
Arm B:
CHART-ED Arm C: IDEAL-CRT Arm D: I-START Arm E: Isotoxic IMRT
CTV V95%>99% V95%>99% V95%>99% V95%>99% Optimal: CTV D(total Vol 
−1 cc) ≥95%
Mandatory: CTVMeanDose±1% of 
prescribed dose
PTV V95%>90%
V90%>98%
V95%>90%
V90%>98%
V95%>90%
V90%>98%
V95%>90%
V90%>98%
Optimal: PTV D(total vol 
−1 cc) ≥90%
PTV D95%≥95%
Mandatory: PTV D(total vol − 
1 cc)≥85%
PTV D95%≥90%
PTV D1 cc≤107%
Spinal canal D0.1 cc<47 Gy D0.1 cc<46 Gy D0.1 cc<48 Gy D0.1 cc<47 Gy D1.0 cc ≤ EQD2 50 Gy
Lung GTV V20 Gy<35% V20 Gy<35% V20 Gy<35% Mean dose≤20 Gy (physical dose)
Brachial plexus D0.1 cc<55 Gy D0.1 cc<64.3 Gy D0.1 cc<65 Gy
D30%<60 Gy (ipsilateral 
branchial plexus)
D0.1 cc<55 Gy D1.0 cc ≤ EQD2 66 Gy
Heart D100%<36 Gy
D67%<44 Gy
D33%<57 Gy
D100%<48 Gy
D67%<57 Gy
D100%<44 Gy
D67%<52 Gy
D33%<59 Gy
D100%<36 Gy
D67%<44 Gy
D33%<57Gy
D1.0 cc ≤ EQD2 76 Gy
Mean dose≤46 Gy (physical dose)
Oesophagus D0.1 cc<105% D0.1 cc<105% D1.0 cc<65 Gy
Lung contra V5 Gy<60%* V5 Gy<60%* V5 Gy<60%*
Mediastinal
envelope
D1.0 cc ≤ EQD2 76 Gy
*Optimal constraint (ie, not mandatory limit).
CTV, clinical target volume; EQD2, equivalent dose for 2 Gray fractions; GTV, gross tumour volume; IMRT, intensity-modulated radiotherapy; PTV, planning target volume.
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Quality of life
Quality of life (QoL) as measured by EuroQol-5D 
(EQ-5D) will be completed at all study visits and weekly 
during treatment.
data collection
All information collected during the course of the study 
will be kept strictly confidential. Data will be entered on 
to an electronic case report form system with built-in edit 
checks to ensure high-quality data. Sites will be monitored 
centrally by checking incoming data for compliance with 
the protocol, data consistency, missing data and timing.
statistical considerations
The comparison of each experimental arm to standard 
treatment has 80% power to detect a 33% increase in 
median PFS (from 8 to 10.7 months) at the 20% one-sided 
level of statistical significance.17 A 33% improvement 
in PFS was selected as it was felt realistic and that an 
improvement of this magnitude was required to ensure 
UK support for any subsequent phase III. There is no 
formal calculation of sample size for the ‘pick-the-winner’ 
element; if more than one experimental arm passes the 
screening threshold, a choice will be made using efficacy, 
toxicity, QoL and health economics (HE) evidence.
Primary analysis
The primary statistical analysis will be based around a 
Cox model fitted to PFS incorporating terms for study 
arm and other prognostic factors that reflect case mix. 
Model fit and the proportional hazards assumption will 
be checked by plotting Schoenfeld residuals and a test for 
goodness-of-fit.18 The assessment of the effect of an exper-
imental arm relative to standard and experimental arms 
relative to one another will be made via the HRs (and 
associated p-values) derived from this model.
Secondary analysis
The analysis of OS and time to local–regional failure will 
be analysed as for PFS.
Toxicity will be assessed using National Cancer Institute 
Common Terminology Criteria for Adverse Event (CTCAE) 
v4.03. Late effects will be monitored. The worst grade will 
summarised and compared between study arms using the 
Mann-Whitney U test. HE analysis will be undertaken from 
the perspective of the UK National Health Service, adhering 
to the National Institute for Health and Care Excellence 
reference case to assess cost-effectiveness of the experimental 
arms compared with current standard. QoL will be assessed 
using EQ-5D and parametric extrapolation undertaken on 
the PFS and OS curves to generate lifetime outcomes and 
compare across study arms in terms of quality-adjusted life 
year gains.
Interim analysis
Study data will be reviewed at least annually by an inde-
pendent data monitoring committee (IDMC). Safety 
stopping in the experimental arms will be monitored 
continuously based on grade 4/5 acute radiation toxicity.
Changes to the protocol after the start of the trial
This document is consistent with ADSCaN study protocol 
(Version 1.2, dated 20 January 2017). There have been 
no significant changes to the protocol since the start of 
the study.
End of the trial
The study will close 12 months after the last patient has 
recruited or when 305 PFS events have been observed 
(whichever is later). The chief investigator and/or the 
TMG have the right at any time to terminate the study for 
clinical or administrative reasons. The end of the study will 
be reported to the research ethics committee and regula-
tory authority (where applicable) within the required time 
frames.
QA programme
The trial is subject to an RT QA programme, which 
includes pre-trial and on-trial components. Dosimetry 
audit will be performed in centres where a recent relevant 
external audit has not been completed. Every attempt 
will be made to streamline with previous national and 
international audits. The QA programme for the study is 
coordinated by the UK RTTQA Group. The details of the 
programme can be found at the RTTQA website, http://
www. rttrialsqa. org. uk.
The pre-trial QA includes:
 ► Facility questionnaire.
 ► Outlining benchmark case. Target volumes and OAR 
are delineated on a CT data set provided. The OAR 
should be outlined according to the ADSCaN OAR 
Atlas.
 ► Planning benchmark case. Planned according to the 
trial protocol on a preoutlined CT (GTV, CTV, PTV 
and OAR).
Centres that have previously completed pre-trial QA 
programmes for the individual trial arms, CHART-ED, 
IDEAL, I-START and Isotoxic IMRT, may be eligible for 
QA streamlining.
The on-trial QA includes individual case reviews (ICRs) 
to monitor protocol adherence:
 ► Prospective ICR for at least the first patient from 
each centre for each trial arm. Retrospective ICR for 
selected cases.
EthICs And dIssEMInAtIon
Adverse events are collected (according to the CTCAE 
V.4.0 grading system) at each trial visit, and all adverse 
events on study are reported to the CRUK CTU Glasgow 
and followed until they resolve or stabilise. Acute and 
late radiation toxicities continue to be recorded at each 
follow-up visit.
trial monitoring and oversight
Formal on-site data monitoring activities are performed 
as part of the ADSCaN study. Each site will receive tele-
phone and on-site monitoring visits during the course of 
the study.
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Data are reviewed by an IDMC (comprising two clinicians 
and one statistician) and Trials Steering Committee. The 
TMG coordinates and manages the trial’s day-to-day activi-
ties and is c of health professionals, a patient representative 
and members of the direct study team, including the prin-
cipal investigators for each of the experimental arms.
dissemination
Data from all centres will be analysed together and 
published promptly. Individual participants may not publish 
data concerning their patients that are directly relevant to 
questions posed by the trial until the TMG has published 
its report. The TMG will form the basis of the Writing 
Committee and advise on publications. The trial will be 
publicised at regional and national conferences. The final 
results will be presented at scientific meetings and published 
in a peer-reviewed journal (authorship will be according to 
the journal’s guidelines). In addition, a lay summary of the 
results will be produced for interested parties, for example, 
CRUK. The CTU is committed to furthering research by 
sharing deidentified individual patient data (IPD) from its 
studies with others in the field who wish to use the data for 
high-quality science and we are happy to consider proposals 
from researchers and will share IPD to the maximum extent.
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